BIOTECanada acknowledges the government’s decision to defer the capital gains tax increase until January 1, 2026. However, delaying the impact does not change the fundamental issue: this policy risks making Canada a less attractive destination for biotech investment and talent. Given where the sector is and where it can go, now is not the time to undermine its momentum.
Ironically, this policy stands to significantly undermine the government’s own investments in growing Canada’s innovation sectors. To maintain Canada’s position as a global biotech leader, policy decisions must reinforce—not weaken—the conditions that enable companies to scale. Investment and talent are geographically agnostic global tourists; they will go to the jurisdictions where they are most valued and can have the most impact.
In this context, it is imperative for Canada to act aggressively and ambitiously to enhance its competitive position. BIOTECanada will continue to advocate for growing the availability and effectiveness of investment capital in the sector to create and drive companies forward.